Neglected Disease Research and Development: Is innovation under threat?
The fourth G-FINDER survey reports on 2010 global investment into research and development (R&D) of new products for neglected diseases, and identifies trends and patterns across the four years of global G-FINDER data. It covers:
- 31 neglected diseases
- 134 product areas for these diseases, including drugs, vaccines, diagnostics, microbicides and vector control products
- Platform technologies (e.g. adjuvants, delivery technologies, diagnostic platforms)
- All types of product-related R&D, including basic research, discovery and preclinical, clinical development, Phase IV and pharmacovigilance studies, and baseline epidemiological studies.
As in previous years, the survey scope was again expanded in order to build a more complete picture of global investment into neglected disease R&D, with a greater focus on Low- and Middle-Income Countries (LMICs) and groups who had historically provided limited data, such as the vector control industry. Public funders in six LMICs – Argentina, Chile, Mexico, Uganda, Nigeria and Malaysia – participated in the survey for the first time. In all, 240 organisations completed the survey in 2010, a 10% increase on 2009.
Visit the Policy Cures website to learn more about the G-Finder reports.